Journal: Oncoscience
Article Title: Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential
doi: 10.18632/oncoscience.647
Figure Lengend Snippet: ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and MD2-overexpressing cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor (MD2-int-1) or vehicle control for 24 h.
Article Snippet: Once tumors were established, as confirmed by IVIS bioluminescence imaging, mice were randomized to receive either vehicle or the selective small molecule MD2 inhibitor, MD2-int-1 (MedChemExpress), for three weeks.
Techniques: Control, Plasmid Preparation